Zobrazeno 1 - 10
of 378
pro vyhledávání: '"John B A G, Haanen"'
Autor:
Lindsay V. M. Leek, Jessica C. L. Notohardjo, Karlijn de Joode, Eline L. Velker, John B. A. G. Haanen, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Jan Willem B. de Groot, Ellen Kapiteijn, Franchette W. P. J. van den Berkmortel, Hans M. Westgeest, Tanja D. de Gruijl, Valesca P. Retel, Edwin Cuppen, Astrid A. M. van der Veldt, Mariette Labots, Emile E. Voest, Joris van de Haar, Alfons J. M. van den Eertwegh
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract We evaluated the prognostic value of hypoalbuminemia in context of various biomarkers at baseline, including clinical, genomic, transcriptomic, and blood-based markers, in patients with metastatic melanoma treated with anti-PD-1 monotherapy
Externí odkaz:
https://doaj.org/article/0b86698c5e3b43c28f9ef4dd875f5025
Autor:
Anastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, Kelly Hoefakker, Bimal Prajapati, Amrita Singh, Annemarie Boerma, Marieke van der Heiden, Sjoukje F. Oosting, Astrid A. M. van der Veldt, T. Jeroen N. Hiltermann, Corine H. GeurtsvanKessel, Anne-Marie C. Dingemans, Egbert F. Smit, Elisabeth G. E. de Vries, John B. A. G. Haanen, Pia Kvistborg, Debbie van Baarle
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionResearch has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains poorly understood.M
Externí odkaz:
https://doaj.org/article/80fab91389fd443aa2a12002abce5698
Autor:
Diane van der Woude, Theo Rispens, Catharina M Korse, Sjoerd H van der Burg, Ellen Kapiteijn, John B A G Haanen, Winan J van Houdt, Els M E Verdegaal, Marij J P Welters, Jessica S W Borgers, Tineke J van Wesemael, Johannes V van Thienen, Kyra A Gelderman, Dirk J A R Moes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)
Introduction Treatment with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) often causes immune-related adverse events (irAEs). Since irAEs resemble autoimmune diseases, autoantibodies might play a role and could potential
Externí odkaz:
https://doaj.org/article/9616b7f6fe8b499baab93acfee17c709
Autor:
Lishi Lin, Aletta P. I. Houwink, Jolanda M. van Dieren, Esther K. Wolthuis, Johannes V. van Thienen, Michiel S. van der Heijden, John B. A. G. Haanen, Jos H. Beijnen, Alwin D. R. Huitema
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Introduction Severe immune‐related adverse events (irAEs) due to immune checkpoint inhibitors (ICIs) can lead to admission to the intensive care unit (ICU). In this retrospective study, we determined the incidence, treatment patterns and s
Externí odkaz:
https://doaj.org/article/b377fea45b7f46209b1c0d057520a529
Autor:
Kalijn F. Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W. van Willigen, Simone Hins-de Bree, Anna L. de Goede, Annemiek J. de Boer, Kevin J. H. Bos, Tjitske Duiveman-de Boer, Michel A. M. Olde Nordkamp, Tom G. M. van Oorschot, Carlijn J. Popelier, Jeanne M. Pots, Nicole M. Scharenborg, Mandy W. M. M. van de Rakt, Valeska de Ruiter, Wilmy S. van Meeteren, Michelle M. van Rossum, Sandra J. Croockewit, Bouke J. Koeneman, Jeroen H. A. Creemers, Inge M. N. Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A. van der Veldt, Dirk J. van Grünhagen, Johanna E. M. Werner, Johannes J. Bonenkamp, John B. A. G. Haanen, Marye J. Boers-Sonderen, Rutger H. T. Koornstra, Martijn F. Boomsma, Erik H. J. Aarntzen, Martin Gotthardt, James Nagarajah, Theo J. M. de Witte, Carl G. Figdor, Johannes H. W. de Wilt, Johannes Textor, Jan Willem B. de Groot, Winald R. Gerritsen, I. Jolanda M. de Vries
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were r
Externí odkaz:
https://doaj.org/article/245269452ff04a81b46a9a6846fb6516
Autor:
Annegien Broeks, Sofie Wilgenhof, John B A G Haanen, Karolina Sikorska, Christian U Blank, Judith M Versluis, Jan Willem B de Groot, Esmee P Hoefsmit, Elisa A Rozeman, Petros Dimitriadis, Aysegul Sari, Daan van den Broek, Disha Rao, Ruben Lacroix, Lindsay G Grijpink-Ongering, Marta Lopez-Yurda, Birthe C Heeres, Bart A van de Wiel, Claudie Flohil, Stijn W T P J Heijmink, Marieke A Vollebergh, Johannes V van Thienen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
Background Continuous combination of MAPK pathway inhibition (MAPKi) and anti-programmed death-(ligand) 1 (PD-(L)1) showed high response rates, but only limited improvement in progression-free survival (PFS) at the cost of a high frequency of treatme
Externí odkaz:
https://doaj.org/article/85f4bb454d4548b7b0eddc4aff9da5e2
Autor:
Maartje W. Rohaan, Emma H. A. Stahlie, Viola Franke, Lisanne P. Zijlker, Sofie Wilgenhof, Vincent van der Noort, Alexander C. J. van Akkooi, John B. A. G. Haanen
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates. Treatment with talimogene laherparepvec (T-VEC), a modified herpe
Externí odkaz:
https://doaj.org/article/7d1e6b458ad644d8942e1babbaf34492
Autor:
Joris L. Vos, Joris B. W. Elbers, Oscar Krijgsman, Joleen J. H. Traets, Xiaohang Qiao, Anne M. van der Leun, Yoni Lubeck, Iris M. Seignette, Laura A. Smit, Stefan M. Willems, Michiel W. M. van den Brekel, Richard Dirven, M. Baris Karakullukcu, Luc Karssemakers, W. Martin C. Klop, Peter J. F. M. Lohuis, Willem H. Schreuder, Ludi E. Smeele, Lilly-Ann van der Velden, I. Bing Tan, Suzanne Onderwater, Bas Jasperse, Wouter V. Vogel, Abrahim Al-Mamgani, Astrid Keijser, Vincent van der Noort, Annegien Broeks, Erik Hooijberg, Daniel S. Peeper, Ton N. Schumacher, Christian U. Blank, Jan Paul de Boer, John B. A. G. Haanen, Charlotte L. Zuur
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Immune checkpoint blockade has become standard care for patients with recurrent metastatic head and neck squamous cell carcinoma (HNSCC). Here the authors present the results of a non-randomized phase Ib/IIa trial, reporting safety and efficacy of ne
Externí odkaz:
https://doaj.org/article/761c20eac4bf4e0f8dc9495fdeadff61
Autor:
Isabella A. J. van Duin, Sjoerd G. Elias, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Willeke A. M. Blokx, Paul J. van Diest, Tim Leiner, Joost J. C. Verhoeff, Rik J. Verheijden, Olivier J. van Not, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, John B. A. G. Haanen, Geke A. P. Hospers, Anna M. Kamphuis, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Marion A. M. Stevense‐den Boer, Marye J. Boers‐Sonderen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk
Publikováno v:
van Duin, I A J, Elias, S G, van den Eertwegh, A J M, de Groot, J W B, Blokx, W A M, van Diest, P J, Leiner, T, Verhoeff, J J C, Verheijden, R J, van Not, O J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Haanen, J B A G, Hospers, G A P, Kamphuis, A M, Piersma, D, van Rijn, R S, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Stevense-den Boer, M A M, Boers-Sonderen, M J, Kapiteijn, E & Suijkerbuijk, K P M 2023, ' Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma ', International Journal of Cancer, vol. 152, no. 12, pp. 2493-2502 . https://doi.org/10.1002/ijc.34479
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can be decades i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6899fe47da203e306ee373387a5e2107
https://doi.org/10.1002/ijc.34479
https://doi.org/10.1002/ijc.34479
Autor:
Anne M May, Michel W J M Wouters, Ellen Kapiteijn, John B A G Haanen, Christian U Blank, Maureen J B Aarts, Rik J Verheijden, Astrid A M van der Veldt, Marye J Boers-Sonderen, Franchette W P J van den Berkmortel, Alfonsus J M van den Eertwegh, Jan Willem B de Groot, Jacobus J M van der Hoeven, Geke A P Hospers, Djura Piersma, Rozemarijn S van Rijn, Albert J ten Tije, Gerard Vreugdenhil, Michiel C T van Zeijl, Karijn P M Suijkerbuijk
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Background Immune checkpoint inhibitor (ICI) can cause severe and sometimes fatal immune-related adverse events (irAEs). Since these irAEs mimick immunological disease, a female predominance has been speculated on. Nevertheless, no demographic or tum
Externí odkaz:
https://doaj.org/article/e9745cefbc3341ff89aba01c2bbe198f